Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 13, 2009

French Authorities Approve Six-Month Formulation of Debiopharm and Ipsen’s Prostate Cancer Drug

  • Debiopharm and its European licensee, Ipsen, confirmed French regulatory clearance for the six-monthly sustained-release formulation of the LHRH agonist, Decapeptyl®, for locally advanced and metastatic prostate cancer. Ipsen says that it expects to launch the drug in France during the first quarter of 2010.

    The six-monthly formulation was approved in October via the European decentralized registration procedure in nine countries: Germany (the reference member state), France, Austria, Finland, Norway, Belgium, Denmark, Spain, and The Netherlands. Regulatory submissions in Portugal, the U.K., Ireland, Italy, Romania, and Lithuania have been filed as national line extensions to existing approvals for other Decapeptyl formulations.

    The therapy is already available in monthly and quarterly sustained-release formulations as well as a daily formulation. It is sanctioned in various markets including the U.S. for the treatment of advanced prostate cancer as well as for indications in endometriosis, precocious puberty, IVF, and uterine fibroids. Debiopharm says worldwide sales by its licensees are over $400 million.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »